Wedd Joel, Bambha Kiran M, Stotts Matt, Laskey Heather, Colmenero Jordi, Gralla Jane, Biggins Scott W
Division of Gastroenterology and Hepatology, University of Colorado Denver, Aurora, CO.
Liver Transpl. 2014 Oct;20(10):1193-201. doi: 10.1002/lt.23929. Epub 2014 Aug 26.
The Model for End-Stage Liver Disease (MELD) score has reduced predictive ability in patients with cirrhosis and MELD scores ≤ 20. We aimed to assess whether a 5-stage clinical model could identify liver transplantation (LT) candidates with low MELD scores who are at increased risk for death. We conducted a case-control study of subjects with cirrhosis and MELD scores ≤ 20 who were awaiting LT at a single academic medical center between February 2002 and May 2011. Conditional logistic regression was used to evaluate the risk of liver-related death according to the cirrhosis stage. We identified 41 case subjects who died from liver-related causes with MELD scores ≤ 20 within 90 days of death while they were waiting for LT. The cases were matched with up to 3 controls (66 controls in all) on the basis of the listing year, age, sex, liver disease etiology, presence of hepatocellular carcinoma, and MELD score. The cirrhosis stage was assessed for all subjects: (1) no varices or ascites, (2) varices, (3) variceal bleeding, (4) ascites, and (5) ascites and variceal bleeding. The MELD scores were similar for cases and controls. Clinical states contributing to death in cases were: sepsis 49%, spontaneous bacterial peritonitis 15%, variceal bleeding 24%, and hepatorenal syndrome 22%. In a univariate analysis, variceal bleeding [odds ratio (OR) = 5.6, P = 0.003], albumin (OR = 0.5, P = 0.041), an increasing cirrhosis stage (P = 0.003), reaching cirrhosis stage 2, 3, or 4 versus lower stages (OR = 3.6, P = 0.048; OR = 7.4, P < 0.001; and OR = 4.1, P = 0.008), a sodium level < 135 mmol/L (OR = 3.4, P = 0.006), and hepatic encephalopathy (OR = 2.3, P = 0.082) were associated with liver-related death. In a multivariate model including the cirrhosis stage, albumin, sodium, and hepatic encephalopathy, an increasing cirrhosis stage (P = 0.010) was independently associated with liver-related death. In conclusion, assessing the cirrhosis stage in patients with low MELD scores awaiting LT may help to select candidates for more aggressive monitoring or for living or extended criteria donation.
终末期肝病模型(MELD)评分在肝硬化且MELD评分≤20的患者中预测能力降低。我们旨在评估一种5期临床模型能否识别出MELD评分低但死亡风险增加的肝移植(LT)候选者。我们对2002年2月至2011年5月期间在一家学术医疗中心等待LT的肝硬化且MELD评分≤20的受试者进行了病例对照研究。采用条件逻辑回归根据肝硬化阶段评估肝相关死亡风险。我们确定了41例病例受试者,他们在等待LT期间于死亡后90天内死于肝相关原因且MELD评分≤20。根据登记年份、年龄、性别、肝病病因、肝细胞癌的存在情况和MELD评分,将病例与最多3名对照(共66名对照)进行匹配。对所有受试者评估肝硬化阶段:(1)无静脉曲张或腹水,(2)静脉曲张,(3)静脉曲张出血,(4)腹水,(5)腹水和静脉曲张出血。病例组和对照组的MELD评分相似。导致病例死亡的临床状态为:脓毒症49%,自发性细菌性腹膜炎15%,静脉曲张出血24%,肝肾综合征22%。在单因素分析中,静脉曲张出血[比值比(OR)=5.6,P=0.003]、白蛋白(OR=0.5,P=0.041)、肝硬化阶段增加(P=0.003),达到肝硬化2、3或4期与较低阶段相比(OR=3.6,P=0.048;OR=7.4,P<0.001;OR=4.1,P=0.008)、钠水平<135 mmol/L(OR=3.4,P=0.006)和肝性脑病(OR=2.3,P=0.082)与肝相关死亡相关。在包括肝硬化阶段、白蛋白、钠和肝性脑病的多变量模型中,肝硬化阶段增加(P=0.010)与肝相关死亡独立相关。总之,评估等待LT的低MELD评分患者的肝硬化阶段可能有助于选择进行更积极监测或活体或扩展标准供体的候选者。